Patents by Inventor Lauren Almeida

Lauren Almeida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED OLIGONUCLEOTIDES
    Publication number: 20230304008
    Abstract: Disclosed herein are compositions comprising modified oligonucleotides. In some embodiments, the oligonucleotide includes a hydrophobic moiety. In some embodiments, the oligonucleotide includes a vinyl phosphonate. In some embodiments, the oligonucleotide includes modified oligonucleotide sugars such as 2? modified ribose molecules. In some embodiments, the oligonucleotide includes modified internucleoside linkages such as phosphorothioate linkages. In some embodiments, the oligonucleotide includes an siRNA. In some embodiments, the siRNA comprises a duplex region with overhangs on either end.
    Type: Application
    Filed: March 27, 2023
    Publication date: September 28, 2023
    Inventors: Darren H. WAKEFIELD, Lauren Almeida, David Rozema, Omri Gottesman, David Lewis
  • COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF ALPHA-1 ANTITRYPSIN
    Publication number: 20230002768
    Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.
    Type: Application
    Filed: June 8, 2022
    Publication date: January 5, 2023
    Applicant: Arrowhead Pharmaceuticals, Inc.
    Inventors: Christine I. Wooddell, David L. Lewis, Darren H. Wakefield, Lauren Almeida, Steven B. Kanner
  • Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin
    Patent number: 11384355
    Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 12, 2022
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Christine I Wooddell, David L Lewis, Darren H Wakefield, Lauren Almeida, Steven B Kanner
  • Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin
    Publication number: 20190284558
    Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.
    Type: Application
    Filed: May 31, 2019
    Publication date: September 19, 2019
    Inventors: Christine I Wooddell, David L Lewis, Darren H Wakefield, Lauren Almeida, Steven B Kanner
  • Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin
    Publication number: 20180258430
    Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 13, 2018
    Inventors: Christine I. Wooddell, David L. Lewis, Darren H. Wakefield, Lauren Almeida, Steven B. Kanner
  • Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin
    Patent number: 10006025
    Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: June 26, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Christine I Wooddell, David L Lewis, Darren H Wakefield, Lauren Almeida, Steven B Kanner
  • Poly(acrylate) polymers for in vivo nucleic acid delivery
    Patent number: 9452221
    Abstract: The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: September 27, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Darren H Wakefield, Nicholas Rossi, David B Rozema, Lauren Almeida, Anthony L Perillo-Nicholas
  • Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin
    Publication number: 20150361427
    Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.
    Type: Application
    Filed: June 16, 2015
    Publication date: December 17, 2015
    Inventors: Christine I Wooddell, David L Lewis, Darren H Wakefield, Lauren Almeida, Steven B Kanner
  • Poly(acrylate) polymers for in vivo nucleic acid delivery
    Patent number: 8933047
    Abstract: The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: January 13, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: Darren H. Wakefield, David B. Rozema, Nicholas Rossi, Lauren Almeida, Anthony L. Perillo-Nicholas
  • Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery
    Publication number: 20130317079
    Abstract: The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Application
    Filed: August 23, 2012
    Publication date: November 28, 2013
    Applicant: ARROWHEAD MADISON INC.
    Inventors: Darren H. Wakefield, David B. Rozema, Nicholas Rossi, Lauren Almeida, Anthony L. Perillo-Nicholas